A recent study published in the Journal of Dermatology proposed that Intravenous Methylprednisolone Pulse therapy (IVMP) is a safe and effective treatment for progressive generalised vitiligo. The main aim of the study was to evaluate the safety and efficacy of IVMP in these patients.
This retrospective study included a review of vitiligo patients’ medical records from their institute. The medical records that were included in the review were between January 2010 and December 2019, for a period of 10 years. A total of 525 vitiligo patients were treated in 10 years, out of which 33 vitiligo patients were aged between 8-78 years, 18 were females and 15 were males.
These patients were treated with IVMP, a daily single course of 500 mg methylprednisolone application for 3 days continuously. Children were administered 8mg/kg per day. Stable condition without lesion progression was observed in 14 of 25 patients (65%) and further repigmentation of above 25% was seen in 12 of 19 patients, 6 months after IVMP therapy. There were no severe adverse effects noted in patients who underwent IVMP therapy.
Thus, the results of the study implied that patients diagnosed with progressive generalised vitiligo can be treated with IVMP therapy as a safe and effective method. Although there are no definitive doses for corticosteroids in vitiligo yet, they are specifically indicated in generalised progressive vitiligo patients.
Source: Wada‐Irimada M, Tsuchiyama K, Sasaki R et al. Efficacy and safety of i.v. methylprednisolone pulse therapy for vitiligo: A retrospective study of 58 therapy experiences for 33 vitiligo patients. J Dermatol. (2021); 48(7):1090-1093.
Source link: https://pubmed.ncbi.nlm.nih.gov/33768620/